Press Releases

Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer

Rockville, Maryland and Hong Kong—February 14, 2019— Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the appointment of Jeff Kmetz as Chief Business Officer. Mr. Kmetz has over 25 years of global pharmaceutical and biotechnology industry experience, most recently serving as Chief Business Officer Read More ›

Ascentage Pharma Announces New License with Unity Biotechnology

Rockville, Maryland and Hong Kong—January 8, 2019—Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Unity Biotechnology, Inc. (Nasdaq:UBX) has selected one of Ascentage’s compounds as its lead development candidate in its ophthalmology pipeline to advance into further preclinical studies to enable an Investigational Read More ›

Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development

Rockville, MD and Hong Kong, and Houston—January 6, 2019—Ascentage Pharma Group, Inc., and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies. The alliance is aimed at developing novel cancer therapeutics based upon Ascentage’s proprietary Protein-Protein Interaction drug discovery Read More ›

Ascentage Pharma Announces Strategic Collaboration with Genor Biopharma

ROCKVILLE, Md. and SUZHOU, China, — December 19, 2018 — Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that it has entered into a strategic collaboration with Genor Biopharma Co. Ltd. (“Genor”). As part of the agreement, the companies will explore the synergies of Ascentage’s MDM2-p53 inhibitor, APG-115, and Genor’s Read More ›

Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting

SAN DIEGO, CA–December 3, 2018–Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for the treatment of cancers, hepatitis B and aging-related diseases, today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the Read More ›

Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting

SUZHOU, China and HONG KONG and ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ — Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies for the treatment of cancers, hepatitis B and aging-related diseases, announced today that the Company will present clinical data of its novel BCR-ABL inhibitor HQP1351 in the upcoming 60th Annual Meeting of the American Society of Read More ›

Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting

ROCKVILLE, Md. and HONG KONG, CHINA /PRNewswire/ – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018. The poster sessions Read More ›

Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting

ROCKVILLE, MD and HONG KONG, CHINA /PRNewswire/ – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that research on its pipeline of small molecule therapeutics will be presented at the 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, April 14-18, 2018. “The Read More ›

Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting

ROCKVILLE, Md. and HONG KONG, CHINA /PRNewswire – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate APG-1252, a novel Bcl-2/Bcl-xL dual inhibitor. The data will be presented by Dajun Yang, Read More ›

Ascentage Pharma Announces Acceptance of IND Application by China FDA for Clinical Study of Novel IAP Inhibitor to Treat Hepatitis B Infection

ROCKVILLE, MD and HONG KONG, CHINA | Ascentage Pharma, a global clinical stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that the China Food and Drug Administration (CFDA) has accepted the Investigational New Drug (IND) application for APG-1387, a novel small molecule IAP inhibitor for the treatment of the Hepatitis B virus (HBV) infection. APG-1387 is the Read More ›